ArticleAnalytical and bioanalytical chemistry2026
Activatable fluorescent nanosensor for real-time detection and intracellular imaging of histone deacetylase 1.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A novel signal-switchable fluorescent biosensing platform was rationally developed based on oxidized single-walled carbon nanohorns (oxSWCNHs) and FAM-labeled peptide probes for the highly sensitive detection, activity evaluation, and intracellular bioimaging of histone deacetylase 1 (HDAC1). The FAM-modified peptide substrate could be tightly adsorbed on the oxSWCNHs. In the presence of HDAC1, the specific deacetylation of acetyl-lysine residues initiated the sequential enzymatic cleavage reaction triggered by carboxypeptidase Y (CPY), which led to the detachment of fluorophores from oxSWCNHs and the obvious recovery of fluorescence signals. Under optimized experimental conditions, the constructed biosensor exhibited excellent sensing performance toward HDAC1 with a low detection limit of 1.4 ng/mL. Meanwhile, the sensing system was effectively utilized to precisely detect HDAC1 in the serum of humans, quantitatively assess the inhibitory effect of trichostatin A (TSA), and achieve intracellular fluorescence imaging of endogenous HDAC1 in living cells. Featuring high sensitivity, favorable specificity, and simple operation, this fluorescent sensing strategy provides a promising and universal tool for clinical HDAC1 analysis, disease-related research and inhibitor screening.
Indexed as
Identifiers
42373812What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.